Key result
Prophylactic vena cava filter insertion was not superior to low-molecular-weight heparin for preventing DVT or PE in immobilized neurosurgical patients.
Why the study?
Does prophylactic vena cava filter insertion prevent symptomatic DVT or PE compared to low-molecular-weight heparin in long-term immobilized neurosurgical patients?
Cohort (n=67)
Does prophylactic vena cava filter insertion prevent symptomatic DVT or PE compared to low-molecular-weight heparin in long-term immobilized neurosurgical patients?
Prophylactic vena cava filter use is not superior to low-molecular-weight heparin for preventing VTE in high-risk, immobilized neurosurgical patients.
Answers are grounded in this paper and cite their sources.
Should not yet change VTE prophylaxis practice in immobilized neurosurgical patients; leaves open the need for randomized confirmation.
AIM: Deep venous thrombosis (DVT) and pulmonary embolism (PE) are the most frequent surgical problems and associated with high morbidity and mortality. Neurosurgical patients constitute a unique group where prophylaxis with anticoagulant and antiaggregant agents are relatively contraindicated due to the natural course of vascular problems such as aneurysms, hemorrhagic tumors or hematomas or increased vulnerability to complex spinal surgeries and trauma. MATERIAL AND METHODS: We included 67 patients predicted to be immobilized for 2 or more months in this retrospective analysis. A vena cava filter was inserted between the first and seventh postoperative day in 40 patients in a prophylactic manner whereas 27 patients received low dose heparin for the same purpose. The patients were evaluated for symptomatic DVT or PE. RESULTS: Percutaneous insertion was performed for all filters without any complication. DVT occurred in two patients of the filter group and 1 patient of the heparin group. There was no PE recorded in any patient of either group. Patients were followed up for 22 months in the filter and 16 months in the heparin group. CONCLUSION: We conclude that prophylactic filter use in high risk neurosurgical patients is not beneficial and not superior to low-molecular-weight heparin use. Nevertheless, it is reasonable to prevent PE in patients with proven DVT who have no contraindication for anticoagulant drugs.
No takes yet. Share an insight, caveat, or question.
Akmangit et al. (2014) conducted a cohort in Immobilized neurosurgical patients (n=67). Vena cava filter vs. Low molecular weight heparin was evaluated on Symptomatic DVT or PE. Prophylactic vena cava filter insertion was not superior to low-molecular-weight heparin for preventing DVT or PE in immobilized neurosurgical patients.
Synapse has enriched 10 related papers. Consider them for comparative context: